糖尿病患之心臟衰竭:談腦型利鈉月太胜(BNP)於糖尿病患之臨床運用

Download (0)

全文

(1)

106 280

BNP

1

1

thiazolidinedione TZD

(BNP)

BNP

TZD BNP (negative predictive value)

BNP TZD

BNP TZD

( Heart failure ) ( Diabetes mellitus )

( BNP )

( Microalbuminuria ) ( Thiazolidinedione )

Thiazolidinedione ( TZD )

1

TZD

2

2

3

( U . S . N a t i o n a l Cholesterol Education Program Adult Treatment Panel III guide-line, NCEP ATP-III guide-line )

2

4

(2)

5

3.8%

6

F r a m i n g h a m H e a r t Study

6.6% 7.9%

2

5

7

Nichols 10,000 2

11.8%

8 9

CONSENSUS 23%

10

SOLVD 23%

11

ValHeFT study

25.9%

12

CHARM study 28.6%

13

3~4

A m a t o 1997

30%

14

15

16

( diabetic cardiomyo- pathy )

17

r e m o d e l - ing

Malmberg 1995 DIGAMI

( 66%)

18

Liu

19

( microalbuminuria )

( LV mass ) BMI ( Body

Mass Index )

Heart Outcomes Prevention Evaluation ( HOPE ) study

20

21

2 2

B e l l Diabetes Care 2003 editorial

23

24

aspirin

25

26

SOLVD

27

study

ACEI ( Angiotensin converting enzyme inhibitors )

blockers ejection fraction

28

remodeling

(3)

BNP

( gold standard )

1981 de Bold ( Atrial natriuretic pep- tide, ANP )

29

, ANP

( Brain na- triuetic peptide BNP ) ( N ) ( N terminal-proBNP, NT-proBNP )

30

BNP

32 ANP

cystine 17

BNP BNP ANP

1 1

ANP BNP

31

NT-proBNP proBNP

endoprotease furin N 1

7 6

B N P

32

BNP 3 B-

NP NT-proBNP

BNP NT-proBNP

BNP NT-proBNP ejection

fraction

33

( PCWP ) ( LVEDV )

34

BNP NT-proBNP

NYHA

35

NT-pro BNP BNP

32

BNP NT-proBNP

ejection fraction

36

BNP

37

BNP

B N P

Maisel 1,586 (dyspnea)

B N P

BNP 100 pg/ml

( sensitivity ) 90%

( specificity ) 76% ( posi- tive predictive value ) 78% ( neg- ative predictive value ) 89% ( accu- racy ) 83%

3 8

BASEL

39

study ( time to discharge ) ( total treatment cost ) ( end p o i n t ) 4 5 2

BNP CHF

26% McDonagh

40

BNP 1,653 25-74

3 . 2 % B N P

17.9pg/ml

77% 87% 55

( subgroup ) 92%

Vasan 3,177 Framingham Heart

Study BNP

BNP

41

B N P

42

B N P B N P

( sensitivity )

( study group ) ( prevalence ) ( negative predictive value )

43

BNP

(4)

P S A

40

( cut off value ) B N P

44

BNP

Epshteyn BNP

< 39pg/ml B N P 9 1 %

BNP > 90 pg/ml

( 96% )

45

Wu Breathing Not Properly Multinational

Study 1,586 922

( subgroup analysis )

( acute dyspnea ) BNP

46

ANP

47

BNP

Wu

B N P

Yano 2

BNP

48

BNP ANP albumin 1-

microglobulin

49

Nagai

B N P

50

51

52

Bell

23

Thiazolidinedione

TZD 3-5%

5 3 , 5 4

sulfonylurea met-

formin 6.0-7.5%

55,56

insulin 15%

57,58

T Z D

59

T Z D

2

2

TZD

60

61

TZD

NYHA I II

III IV T Z D

T Z D 3

X B N P

T Z D

BNP Thiazolidinedione

Ogawa

62

2

pioglitazone 15 mg/day 48 pioglitazone

( BNP 100 pg/ml )

( Base-line ) BNP

( 18pg/ml ) BNP

(5)

pioglitazone BNP

buformin BNP

B N P A N P

pioglitazone Ogawa

2 BNP piogli-

tazone 2

B N P pioglitazone BNP

B N P

B N P

B N P

T Z D

BNP ( negative predictive value )

B N P

Ogawa TZD

B N P

B N P

B N P

T Z D

BNP BNP

T Z D

BNP TZD

1.Masoudi FA, Wang Y, Inzucchi SE, et al. Metformin and thia- zolidineone use in medicine patients with heart failure. JAMA 2003; 290: 81-5.

2.Nesto R, Bell D, Bonow RO, et al. Thiazolidinedione use, fluid retension, and congestive heart failure: a consensus statement from the American Heart Association and the American Diabetic Association. Circulation 2003; 108: 2941-8.

3.Haffner SM, Lehto S, Ronnemaa T, et al. Mortality from coro- nary heart disease in subject with type 2 diabetes and in nondi- abetic subject with without prior myocardial infarction. N Engl J Med 1998; 339: 229-334.

4.Expert panel on detection, evaluation, and treatment of high blood cholesterol in adult. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Asult Treatment Panel III. JAMA 2001; 285: 2486-97.

5.Cowie MR, Mosterd A, Wood OA, et al. The epidemiology of heart failure. Eur Heart J 1997; 18: 208-15.

6.McDonagh TA, Morrison CE, Lawrence A, et al. Symptomatic and asymptomatic left ventricular systolic dysfunction in urban population. Lancet 1997; 350: 829-33.

7.Kannel WB, Hjortland M, Castelli WP. Role of diabetes in con- gestive heart failure: the Framinghan study. Am J Cardiol 1974;

34: 29-34.

8.Nichols GA, Hiller TA, Erbey JR, et al. Congestive heart failure in type 2 diabetes: prevalence, incidence, and risk factors.

Diabetes Care 2001; 24: 1614-9.

9.Hunt SA, Baker DW, Chin MH, et al. ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult: executive summary: a report of the American College of Cardiology /American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2001; 38: 2101-13.

10.The CONSENSUS trial study group. Effect of enalapril on mor- tality in mortality in severe congestive heart failure. N Engl J Med 1987; 316: 1429-35.

11.Shindler DM, Kostis DM, Kostis JB, et al. Diabetes mellitus, a predictor of morbidity and mortality in the Studies of Left Ventricular Dysfunction (SOLVD) Trials and Registry. Am J Cardiol 1996; 77: 1017-20.

12.Cohn JN, Tognoni G. For the valsartan heart failure trial inves- tigators. A randomized trial of the angiotensin-receptor block- er valsartan in chronic heart failure. N Engl J Med. 2001; 345:

1667-75.

13.McMurray J, Ostergren J, Dfeffer M, et al. Clinical feature and contemporary management of patients with low and preserved ejection fraction heart failure: baseline characteristics of patients in the Candesartan in Heart failure-Assessment of Reduction in Mortality and Morbidity ( CHARM ) program. Eur J Heart Fail 2003; 5: 261-70.

14.Amato L, Paolisso G, Cacciatore F, et al. Congestive heart fail-

(6)

ure predicts the development of non-insulin-dependent diabetes mellitus in the elderly: the Osservatorio Geriatrico Regione Campania Group. Diabetes Metab 1997; 23: 213-8.

15.Gheroghiade M, Bonow RO. Chronic heart failure in the United States: a manifestation of coronary artery disease. Circulation 1998; 97: 282-9.

16.Brooks RC, Deter KM. Clinical trials of revascularization ther- apy in diabetes. Current Opinion in Cardiology 2000; 15: 287- 92.

17.Hirayama H, Sugano M, Abe N, et al. Troglitazone, an antidia- betic drug, improves left ventricular mass and diastolic function in normation in normatensive diabetic patients. Int J Cardiol 2001; 77: 75-9.

18.Malmberg K, Ryden L, Efendic S, et al. Randomized trial of in- sulin-glucose infusion followed by subcutaneous insulin treat- ment in diabetic patients with acute myocardial infarction (DIGAMI study): effect on mortality at 1 year. J Am Coll Cardiol 1995; 26: 51-65.

19.Liu JE, Robbins DC, Palmieri V, et al. Associatition of albu- minuria with systolic and diastolic left ventricular dysfunction in type 2 diabetes. The Strong Heart Study. J Am Coll Cardiol 2003; 42: 2022-8.

20.Arnol JM, Yusuf S, Young J, et al. Prevention of heart failure in patients in the Heart Outcome Prevention Evaluation (HOPE) study. Circulation 2003; 107: 1284-90.

21.Bell DSH. Heart failure. The frequent, forgotten, and often fa- tal complication of diabetes. Diabetes Care 2003; 26: 2433-41.

22.Gerstein HG, Mann JF, Yi Q, et al. For the HOPE study inves- tigators. Albuminuria and risk of cardiovascular events, death, and heart failure, in diabetic and nondiabetic individuals. JA- MA 2001; 286: 421-6.

23.Bell DSH. Diabetic cardiomyopathy. Diabetes Care 2003; 26:

2949-51.

24.Saint Vincent Declaration, Diabetes Mellitus in Europe: A prob- lem at all ages in all countries. A Model for Prevention and Self Care. Saint Vincent (Italy) 10-12 October 1989. A meeting or- ganization by WHO and IDF in Europe. ( http://www.idf.org/

webdata/docs/SVD%20and%20Istanbul%20commitment.pdf ) 25.Sayer JW, Timmis AD. Investigation of coronary artery disease in diabetes: is screening of asymptomatic patients necessary?

Heart 1997; 79: 525-6.

26.Margolis JR, Kannel WB, Feinleib M, et al. Clinical features of unrecognized myocardial infarction-silent and symptomatic.

Eighteen year follow-up: the Framingham study. Am J Cardiol 1973; 32: 1-7.

27.The SOLVD investigators. Effect of enalapril on mortality and the development of the heart failure in asymptomatic patients necessary? Heart 1997; 78: 525-6.

28.Bristow MR, Roden RL, Lowes BD, et al. The role of third-gen- eration beta-blocking agents in chronic heart failure. Clin Cardiol 1998; 21: I3-13.

29.de Bold AJ, Borenstein HB, Veress AT, et al. A rapid and potent natriuretic response to intravenous injection of atrial myocar-

dial extract in rats. Life Science 1981; 28: 89-94.

30.Lainchbury JG, Campbell E, Frampton CM, et al. Brain natri- uretic peptide and N-terminal brain natriuretic peptide in the di- agnosis of heart failure in patients with acute shortness of breath.

J Am Coll Cardiol 2003; 42: 728-35.

31.Luchner A, Stevens TL, Borgeson DD, et al. Differential atrial and ventricular expression of myocardial BNP during evolution of heart failure. Am J Physiol 1998; 274: H1684-9.

32.Hunt PJ, Richards AM, Nicholls MG, et al. Immunoreactive amino-terminal pro-brain natriuretic peptide (NT-PROBNP): a new maker of cardiac impairment. Clin Endocrinol 1997; 47:

287-90.

33.Davis M, Espiner E, Richards G, et al. Plasma brain natriuretic peptide in assessment of acute dyspnea. Lancet 343: 440-4.

34.Richards AM, Crozier IG, Yandle TG, et al. Brain natriuretic factor: regional plasma concentration and correlations haemo- dynamic state in cardiac disease. Br Heart J 1993; 69: 414-7.

35.Wieczorek SJ, Wu AH, Christenson R, et al. A rapid b-type na- triuretic peptide assay accurately diagnosis left ventricular dys- function and heart failure: a multicenter evaluation. Am Heart J 2002; 144: 834-9.

36.Omland T, Aakvaag A, Bonarjee VV, et al. Plasma brain natri- uretic peptide as an indicator of left ventricular systolic function and long-term survival after acute myocardial infarction: com- parison with plasma atrial natriuretic peptide and N-terminal protrical natriuretic peptide. Circulation 1996; 93: 1963-9.

37.Yu CM, Sanderson JE, Sham IOL, et al. Diastolic dysfunction and natriuretic peptides in systolic heart failure. Higher ANP and BNP levels are associated with the restrictive filling pattern.

Eur Heart J 1996; 17: 1694-702.

38.Maisel AS, Krishnaswamy P, Nowak RM, et al. Rapid mea- surement of B-type natriuretic peptide in the emergency diag- nosis of heart failure. N Engl J Med 2002; 347: 161-7.

39.Mueller C, Scholer A, Laule-Kilian K, et al. Use of B-type na- triuretic peptide in the evaluation and management of acute dys- pnea. N Engl J Med 2004; 350: 647-54.

40.McDonagh T, Robb SD, Murdoch DR, et al. Biochemical de- tection of left ventricular systolic dysfunction. Lancet 1998; 351:

9-13.

41.Vasan RS, Benjamin EJ, Larson MG, et al. Plasma natriuretic peptides for community screening for left ventricular hyper- tropathy and systolic dysfunction. JAMA 2002; 228: 1252-9.

42.Wang TJ, Larson MG, Levy D, et al. Plasma natriuretic peptide levels and the risk of cardiovascular events and death. N Engl J Med 2004; 350: 655-63.

43.Remme WJ, Swedberg K. Task force for the diagnosis and treatment of chronic heart failure, European Society of Cardiology. Eur Heart J 2001, 22: 1527-60.

44.de Lemos JA, McGuire DK, Drazner MH. B-type natriuretic peptide in cardiovascular disease. Lancet 2003; 362: 316-22.

45.Epshteyn V, Mudaliar S, Morrion K, et al. Utility of B-type

Natriuretic Peptide (BNP) as a screen for left ventricular

dysfunction in patients with diabetes. Diabetes Care 2003; 26:

(7)

2081-7.

46.Wu AHB, Storrow AB, OMland T. The effect of diabetes on B- type Natriuretic Peptide Concentrations in patients with acute Dyspnea. An analysis from the Breathing Not Properly Multinational Study. Diabetes Care 2004; 27: 2398-404.

47.Ferri C, Piccolo A, Laurenti O, et al. Atrial natriuretic factor in hypertensive and normatensive diabetic patients. Diabetes Care 1994; 17: 195-200.

48.Yano Y, Katsuki A, Gabazza EC, et al. Plasma brain natriuretic peptide levels in normotensive noninsulin-dependent diabetic patients with microalbuminuria. J Clin Endocrinol Metab 1999;

84: 2353-6.

49.Mckenna K, Smith D, Moore K, et al. Brain natriuretic peptide increases urinary albumin and alpha-1 microglobulin excretion in type 1 diabetes mellitus. Diabet Med 2001; 18: 973-8.

50.Nagai T, Imamura M, Inukai T, et al. Brain batriuretic polypep- tide in type 2 diabetes patient with albuminuria. J Med 2001; 32:

169-80.

51.Wachtell K, Palmieri V, Olsen MH, et al. Urine albumin/creati- nine ratio and echocardiographic left ventricular function in hy- pertensive patient with electrocardiographic eft ventricular hy- pertrophy: The LIFE study. Am Heart J 2002; 143: 319-26.

52.Viazzi F, Parodi D, Leoncini G, et al. Optimizing global risk evaluation in primary hypertension: the role of microalbumin- uria and cardiovascular ultrasonography. J Hyperytens 2004; 22:

907-13.

53.Takeda Pharmaceuticals. Actos (pioglitazone) package insert.

Lincolnshire IL.

54.GlaxoSmithKline Pharmaceuticals. Avandia (rosiglitazone) package insert.

55.Belcher GL, Michel JL. Tolerability profile of pioglitazone in combination with a sulfonylurea or metformin in controlled clin- ical trials. Diabetes 2001; 50 (suppl 2): A416.

56.Aronoff SL. Adverse events with pioglitazone. Diabetes 2000;

49 (suppl 1): A340-1.

57.Raskin P, Rendell M, Riddelle MC, et al. A randominzed trial of rosiglitazone therapy in patients with inadquately controlled insulin-treated type 2 diabetes. Diabetes Care 2001; 24: 1226- 32.

58.Rubin C, Egan J, Schacider R. Combination therapy with pi- oglitazone and insulin in patients with type 2 diabetes. Diabetes 1999; 48 (suppl 1): A110.

59.Karter AJ, Ahmed AT, Liu J, et al. Use of thiazolidinediones and risk of heart failure in people with type 2 diabetes: a retrospective cohort study ( Letter ). Diabetes Care 2004; 27: 850-1.

60.St. John Sutton M, Rendell M, Dandona P, et al. A comparison of the effect of rosiglitazone and glyburide on cardiovascular function and glycemic control in patient with type 2 diabetes.

Diabetes Care 2002; 25: 2058-64.

61.Nesto RW, Winter ML, Bell D, et al. Thiazolidinedione use, fluid retention, and congestive heart failure. A consensus statement from the American Heart Association and American Diabetes Association. Diabetes Care 2004; 27: 256-63.

62.Ogawa S, Takeuchi K, Ito S. Plasma BNP level in the treatment

of the Type 2 diabetes with pioglitazone. J Clin Endocrinol

Metab 2003; 88: 3993-6.

(8)

Diabetes Mellitus and Heart Failure the Potential Implication

of Brain Natriuretic Peptide (BNP)

Ching-Ling Lin, Shinn-Tzong Gong, and Herng-Cheng Chiou

1

As the use of thiazolidinedione (TZD) becomes more popular, there is a growing concern that fluid reten- tion associated with TZD use may precipitate or induce heart failure in patients with diabetes mellitus. Diabetes mellitus is an independent risk factor of heart failure; more attention must be given to this issue so that the out- come for this group of CAD equivalent patients can be improved. Traditionally echocardiography with dopplar ul- trasound is the gold standard for the diagnosis of heart failure. However, the cost and technical cumbersome pre- clude it from being a full-scale screening tool. Plasma brain natriuretic peptide (BNP) level is closely correlated with both diastolic and systolic cardiac function, however the use of BNP for screening of cardiac dysfunction should be restricted to certain high-risk group. For diabetic patients with TZD associated edema the high nega- tive predictive value of BNP may be useful for identifying patients who need further diagnostic evaluation. For diabetic patients with microalbuminuria and elevated BNP level prior to TZD administration, the risk of heart fail- ure is higher than those without microalbuminuria. For this particular group of patients echocardiographic study should include a complete evaluation of diastolic dysfunction. ( J Intern Med Taiwan 2005; 16: 63-70 )

Endocrinology and Metabolism,

1

Cardiology Department of Internal Medicine,

Cathay General Hospital

數據

Updating...

參考文獻

相關主題 :